Latest Research, Industry, Medical and Scientific News
A medical device for treating constipation and faecal incontinence has been recommended for health service use by the National Institute for Health and Care Excellence. Specialist stoma care nurses working with both children and adults affected by faecal continence problems welcomed the decision by NICE to back the use of the Peristeen transanal irrigation system.In new medical technology guidance published today, NICE said the “case for adopting” the Peristeen for managing bowel dysfunction was “supported by the evidence”. According to NICE, the system can “reduce the severity of constipation and incontinence, improve quality of life and promote dignity and independence”. Read more.
Source: Nursing Times, February 23, 2018
BewellConnect recently unveiled their new pelvic floor muscle trainer to help women with related issues, including post-partum complications and incontinence. The MyPeriTens device is both an electrical nerve stimulator and electrical muscle stimulator that is controlled through a smartphone app, allowing women to have precise control over the intensity and nature of the electrical signals delivered. The smartphone app has a number of routines built in that the woman can perform on her own, or with assistance of a physical therapist. Each routine can be selected to run at the patient’s preferred intensity level, maximizing benefits while keeping any pain and discomfort at a minimum. Read more.
Source: Medgadget, February 15, 2018
For a chronic health condition that causes shame and misery for countless people and costs billions, urinary incontinence keeps a low profile. Media reports about chronic health conditions appear with alarming regularity, but it is rare to read about the debilitating impact of the involuntary leakage of urine. Nevertheless, urinary incontinence is a condition which, next to Alzheimer’s or strokes, is reported as most negatively affecting “health-related quality of life”. The reasons for this are not too hard to fathom. Urinary incontinence, of course, elicits some embarrassment. And there also seems to be a feeling this is a low priority condition: urinary incontinence does not directly bear up against the terrible impacts of life threatening conditions and illnesses. Read more.
Source: The Conversation, February 14, 2018
Scientists from the University of Sheffield have developed a material that could be used as an alternative to the current vaginal mesh material, polypropylene, used to treat pelvic organ prolapse and stress urinary incontinence. The use of these current meshes, in particular surgical procedures, has led to severe complications for millions of women across the world and is now banned in Australia. The research conducted by the University of Sheffield, published today in the journal Neurourology and Urodynamics, provides evidence which supports the use of a softer and more elastic material better suited for use in the pelvic floor and one that releases oestrogen into the surrounding pelvic tissue to form new blood vessels and ultimately speed up the healing process. Read more.
Source: EurekAlert, February 13, 2018
Innovus Pharmaceuticals, Inc. (“Innovus Pharma” or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women’s health and respiratory diseases, today announced that the human clinical trial for the patented formulation in its product UriVarx® product for bladder health was published in the peer reviewed journal, BMC Complementary and Alternative Medicine (Schoendorfer et al. BMC Complementary and Alternative Medicine (2018) 18:42). The study was conducted by the team of Dr. Niikee Schoendorfer in Australia in collaboration with the Company’s UriVarx® licensing partner Seipel Group, Ltd. The outcome of this study demonstrated both statistical significance and clinical relevance in reducing symptoms of Overactive Bladder (“OAB”), urinary frequency and/or urgency and incontinence. Read more.
Source: Digital Journal, February 7, 2018
New Zealand’s regulatory body Medsafe has taken steps to remove a number of surgical mesh products from the country, according to a release posted today. The agency said the product’s removal was the outcome of a recent regulatory action on surgical mesh products, specifically those designed for treating pelvic organ prolapse via transvaginal implantation and one mini-sling product designed to treat stress urinary incontinence. Medsafe said that last December it requested safety information from four surgical mesh suppliers in New Zealand, following action taken by Australia’s TGA as it looked to review meshes used for urogynaecological use. The earlier TGA’s investigation ended in regulatory actions to remove the devices from the market, MedSafe said, and similarly resulted in their removal from New Zealand’s market. Read more.
Source: +Mass Device, January 31, 2018